188 related articles for article (PubMed ID: 18429968)
21. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse.
Zhang Y; Wang H; Unadkat JD; Mao Q
Drug Metab Dispos; 2007 Dec; 35(12):2154-8. PubMed ID: 17785426
[TBL] [Abstract][Full Text] [Related]
23. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2.
Wang X; Morris ME
Drug Metab Dispos; 2007 Feb; 35(2):268-74. PubMed ID: 17093006
[TBL] [Abstract][Full Text] [Related]
24. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.
Merino G; Jonker JW; Wagenaar E; van Herwaarden AE; Schinkel AH
Mol Pharmacol; 2005 May; 67(5):1758-64. PubMed ID: 15709111
[TBL] [Abstract][Full Text] [Related]
25. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
[TBL] [Abstract][Full Text] [Related]
26. Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions.
Sakiyama M; Matsuo H; Takada Y; Nakamura T; Nakayama A; Takada T; Kitajiri S; Wakai K; Suzuki H; Shinomiya N
Drug Metab Pharmacokinet; 2014; 29(6):490-2. PubMed ID: 24869748
[TBL] [Abstract][Full Text] [Related]
27. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
Merino G; van Herwaarden AE; Wagenaar E; Jonker JW; Schinkel AH
Mol Pharmacol; 2005 May; 67(5):1765-71. PubMed ID: 15722455
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
[TBL] [Abstract][Full Text] [Related]
29. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
30. Telmisartan pharmacokinetics in Japanese renal transplant recipients.
Miura M; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
Clin Chim Acta; 2009 Jan; 399(1-2):83-7. PubMed ID: 18838068
[TBL] [Abstract][Full Text] [Related]
31. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
32. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.
Kobayashi D; Ieiri I; Hirota T; Takane H; Maegawa S; Kigawa J; Suzuki H; Nanba E; Oshimura M; Terakawa N; Otsubo K; Mine K; Sugiyama Y
Drug Metab Dispos; 2005 Jan; 33(1):94-101. PubMed ID: 15475413
[TBL] [Abstract][Full Text] [Related]
33. Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.
Oh ES; Kim CO; Cho SK; Park MS; Chung JY
Drug Metab Pharmacokinet; 2013; 28(3):196-202. PubMed ID: 23007012
[TBL] [Abstract][Full Text] [Related]
34. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.
Kim KA; Joo HJ; Park JY
Eur J Clin Pharmacol; 2011 Feb; 67(2):129-34. PubMed ID: 20972558
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
Sugimoto Y; Tsukahara S; Ishikawa E; Mitsuhashi J
Cancer Sci; 2005 Aug; 96(8):457-65. PubMed ID: 16108826
[TBL] [Abstract][Full Text] [Related]
36. Interindividual Regulation of the Breast Cancer Resistance Protein/
Bircsak KM; Moscovitz JE; Wen X; Archer F; Yuen PYS; Mohammed M; Memon N; Weinberger BI; Saba LM; Vetrano AM; Aleksunes LM
Drug Metab Dispos; 2018 May; 46(5):619-627. PubMed ID: 29386232
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.
Xia CQ; Yang JJ; Gan LS
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):595-611. PubMed ID: 16863427
[TBL] [Abstract][Full Text] [Related]
38. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Li R; Barton HA
Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
[TBL] [Abstract][Full Text] [Related]
39. Genetic analysis of ABCG2 gene C421A polymorphism with gout disease in Chinese Han male population.
Wang B; Miao Z; Liu S; Wang J; Zhou S; Han L; Meng D; Wang Y; Li C; Ma X
Hum Genet; 2010 Feb; 127(2):245-6. PubMed ID: 19921266
[No Abstract] [Full Text] [Related]
40. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
Ripperger A; Benndorf RA
Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
